



IND OPEN MEETING

CHELSEA HOTEL, TORONTO, ON
ROOM: MOUNTBATTEN SALON
FRIDAY APRIL 27, 2018, 9:00 AM – 12:00 PM

CO-CHAIRS : DR. PHILIPPE BEDARD & DR. ROSALYN JUERGENS
IND PROGRAM DIRECTOR : DR. LESLEY SEYMOUR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To summarize aspects of recent developments in the understanding of immunotherapy, novel therapeutic agents as these relate to specific malignancies and their therapeutic targets.
- To describe and discuss results of recent Investigational New Drug studies conducted by the CCTG.
- To explain aspects new clinical trial methodologies in the field of early cancer drug development.

9:00 am	Welcome	
9:05 am	IND Team Awards announced	Philippe Bedard
9:10 am	Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award & Lecture: IND.231	John Hilton
9:40 am	CCTG & CRI collaboration	Aiman Shalabi, Cancer Research Institute
10:10 am	Coffee break	
10:25 am	Trial updates:	
	a) IND.228	a) Abha Gupta
	b) IND.214	b) Derek Jonker
	c) IND.223/224	c) Kim Chi
	d) IND.227	d) Quincy Chu
11:05 am	Current trials:	
	a) IND.225	Lesley Seymour
	b) IND.226	
	c) IND.217	
	d) IND.222	
	e) IND.224	
	f) IND.232	
11:30am	Planned trials:	
	a) IND.235	a) – c) Martin Smoragiewicz
	b) IND.236	
	c) Durvalumab rechallenge	
	d) CFI-400945 single agent multi-arm PII	d) – f) David Cescon
	e) CFI-402257 single agent PII	
	f) Durvalumab + CFI-400945	
11:55am	Closing remarks	Philippe Bedard